8/6/2026

Samsung, SK Hynix Shareholders Call for Bigger Payouts From AI Cash Mountain

Reuters (08/06/26) Jin, Hyunjoo; Tanishk, Kumar

Samsung Electronics (005930.KS) and SK Hynix (000660.KS) face growing calls from investors wanting a greater share of excess cash via dividends or buybacks, after the pair provided scant detail on capital returns when reporting AI-driven record profit. The world's two largest memory chip makers are generating cash at an unprecedented pace due to robust demand for chips used in AI applications, amassing reserves that exceed those of U.S. tech giants that are spending heavily on AI infrastructure. Samsung and SK Hynix are set to hold a combined $263 billion in net cash by year-end, more than double the estimated $102 billion of AI bellwether Nvidia (NVDA.O) and exceeding the combined cash of the other six "Magnificent Seven" U.S. technology companies, LSEG data and Reuters calculations showed. AI frenzy has seen share prices of companies anywhere in the value chain soar spectacularly over the past year, but plummet equally spectacularly as euphoria over the technology's potential wrestles with concern over huge outlay and skepticism about corresponding returns. With such companies reporting record profit, an absence of plans to commit to larger shareholder payouts could be interpreted as management being unconvinced about the durability of AI earnings, investors and analysts said. In the case of Samsung and SK Hynix, the wait for payout plans stings all the more as the firms lag international technology peers such as Apple (AAPL.O) and TSMC (2330.TW) in shareholder returns – sentiment exacerbated by broader investor discontent about the so-called Korea discount. At present, both Samsung and SK Hynix target shareholder returns equivalent to half of free cash flow. In June, U.S. chipmaker Micron (MU.O) pledged to return 100%. "If you stick to something around a 50% free cash flow return, you are going to end up with an incredibly inefficient balance sheet," said London-based portfolio manager Richard Clode at Janus Henderson Investors, whose fund owns SK Hynix shares. "If you come out and say, 'Well, we're a bit unsure about the future, so we can't commit to a long term, big shareholder return program,' then you're just feeding the narrative that this is temporary, this is cyclical," he said. During an earnings call last week, SK Hynix said only that it was considering additional measures to enhance returns and that it would share plans within this year. "I was really infuriated after the call," said portfolio manager Kim Kyu-shik at Singapore-based hedge fund Vista Global Asset Management. "Shareholders were listening to the call for some sign of hope." SK Hynix and Samsung shares have retreated around 48% and 37% respectively from record highs reached in June. "I think they understand the urgency and the dislocation in the market today," said Clode, calling for an increase in SK Hynix returns to at least 80% of free cash flow. JPMorgan (NYSE: JPM) analysts on Wednesday cut their target price for SK Hynix stock, saying a "clear stance on capital allocation is imperative ... to restore stock sentiment." "Based on record-high cash generation capabilities, the company believes that it can meaningfully expand shareholder returns while maintaining investments and financial soundness," SK Hynix said in a statement. Samsung said it is discussing its shareholder returns policy for this year and beyond and aims to share details "very soon." "While we remain focused on maintaining a healthy balance sheet to manage cyclical risks and fund growth initiatives, we are also exploring ways to enhance shareholder returns in a sustainable manner," Samsung said in a statement. Some investors have begun pressing for larger returns and increased efficiency in capital allocation including limiting employee bonuses. "Retail investors are scared after the recent share-price plunge," said Lee Sang-mok, a representative at ACT. The retail investor platform this week launched a campaign to compel Samsung to hold an extraordinary shareholders' meeting and conduct a $32 billion share buyback. "It seems like there is a lack of urgency at Samsung and SK Hynix." Samsung has historically maintained a large cash reserve as the memory chip business is capital-intensive and prone to boom-and-bust cycles. This year, Samsung and SK Hynix pledged a combined 3,200 trillion won ($2.07 trillion) in domestic investment to meet AI demand. The pair are securing multi-year supply deals with major customers which should help them avoid the excessive capacity expansion that marked previous boom periods, freeing more cash for shareholder returns, said analyst Park Jun-young at Hanwha Investment & Securities. "Given their expected cash generation, both companies should be capable of funding these investments while also delivering materially stronger shareholder returns," said Aadil Ebrahim, group head of equities at Klay Group. It was not a "binary choice" between investment and shareholder returns, he said. The issue has broader implications regarding government efforts to address the Korea discount, or a tendency for Korean companies to trade at lower valuations than peers partly due to lower shareholder returns. Ebrahim cited Apple's capital-return program from 2013 as a precedent for a cash-rich technology company. At the time, the firm planned to return $100 billion through 2015 which included boosting a share buyback program six-fold to $60 billion. "Improving capital allocation could play an important role in narrowing that discount over time," Ebrahim said. Stronger shareholder returns could drive a long-term re-rating of South Korean equities, he said.

Read the article

8/6/2026

Hedge Fund Turning Up Pressure on Voya Financial to Sell Itself

Wall Street Journal (08/06/26) Thomas, Lauren; Maurer, Mark

Hedge fund Toms Capital Investment Management (TCIM) is ratcheting up the pressure on asset manager Voya Financial (NYSE: VOYA) by bringing its push for the firm to explore a sale directly to shareholders, according to a letter seen by The Wall Street Journal. TCIM holds a roughly 4.5% stake in Voya, making it one of the company’s largest shareholders, according to the open letter the firm plans to send to shareholders Thursday. Voya has a market value of around $9 billion. Its shares have climbed more than 30% over the past 12 months, with the rally driven in part by takeover speculation. TCIM has been privately pushing Voya for months to evaluate strategic alternatives, including an outright sale of the business, to no avail, the letter said. In June, TCIM publicized a letter disclosing that it held a sizable position in Voya and calling on the company to move ahead with a formal strategic review, at a time of rapid consolidation in the asset-management industry. TCIM now plans to call for a vote of no confidence in Voya’s current management team and board, according to the letter. Voya’s most recent annual meeting was held in May. TCIM plans to file proxy materials Thursday, which would precede a meeting to count the vote, the letter said. Voya declined to comment. The hedge fund is hoping to send a message that Voya should commit to running a strategic review and abandon efforts to turn around its insurance business, particularly its stop-loss business, according to the letter. TCIM argued in its letter that Voya has underperformed and that the company’s board has failed to hold management accountable and move quickly enough to address shareholder concerns. Voya Chief Executive Heather Lavallee, in response to an analyst’s question about TCIM on an earnings call Wednesday, said the firm’s doesn’t comment on “rumors or headlines nor do we allow ourselves to get distracted by it.” Lavallee added, “At the end of the day, the board and management, we’re always going to do what is in the best long-term interest of shareholders. That includes restoring the stop-loss business to the target margins that we have talked about.” TCIM said that while it believes that Voya’s retirement and investment-management businesses are strong franchises, Voya trades at a discount to its peers in large part because it hasn’t given up on its stop-loss business, which shields self-insured employers from costly employee health claims. Potential buyers for all of Voya—or for its stop-loss business—could include Empower, part of Great-West Lifeco (OTCMKTS: GWLIF); Principal Financial (NASDAQ: PFG); and Sun Life (NYSE: SLF), according to a Raymond James note. TCIM, which has about $3.8 billion of assets under management, rarely gets involved in public investor fights and is known for engaging with companies behind the scenes. The hedge fund had never formally issued a public statement about one of its investments prior to Voya. The firm, co-founded by Ben Pass, has built positions at major U.S. companies including Target (NYSE: TGT), Pringles and Pop-Tart parent Kellanova (now owned by Mars), railroad company CSX (NASDAQ: CSX), and Tylenol maker Kenvue (NYSE: KVUE).

Read the article

8/6/2026

Alkami Kicks Off Sale Process After Buyer Interest, Sources Say

Reuters (08/06/26) Vinn, Milana

Digital banking software provider Alkami Technology (ALKT.O) has formally launched a sale process after drawing acquisition interest from potential buyers amid mounting pressure from Jana Partners, according to people familiar with the matter. The Plano, Texas-based company's advisers began contacting private equity firms over the past week following the inbound interest, the sources said. The discussions are in their early stages and no deal is guaranteed, the sources said, speaking on condition of anonymity because the matter is confidential. Alkami did not immediately respond to a request for comment. The process comes on the back of Jana Partners contending Alkami was failing to run a genuine sale process, according to a Bloomberg report last month. Alkami provides cloud-based digital banking software and related services to banks and credit unions, including account opening, payments, fraud protection, data analytics and customer engagement tools. Jana disclosed a 5.1% stake in Alkami in April after building its position in the company in 2025. Reuters previously reported that the hedge fund believed Alkami's shares were undervalued and had urged the company to explore a sale to a strategic buyer or private equity firm. Alkami has a market value of about $2 billion. Its shares have fallen about 15% over the past 12 months amid concerns over slowing growth and a tougher spending environment for financial technology companies.

Read the article

8/5/2026

Mayne Pharma Investors Push for Break-Up After Blocked Takeover Bid

Australian Financial Review (08/05/26) Smith, Michael

Mayne Pharma (ASX: MYX) investors are calling for the sale of its women’s health and dermatology businesses in the United States, after the federal government’s decision to block a takeover of the Adelaide-based company last year left them nursing heavy losses. Key shareholders, including offshore hedge funds and investors who now make up more than 20% of Mayne’s share register, are putting pressure on chairman Bruce Robinson to start a strategic review of the group’s assets. This follows Treasurer Jim Chalmers’ shock move last year to block a $672 million takeover bid for Mayne by U.S. private-equity backed Cosette on national interest grounds. Cosette had spent months in court trying to back out of the $7.40 per share offer, arguing that there had been a material adverse change in Mayne’s financial position. Mayne shares now trade at less than half that amount, and investor frustration came to a head late last week when the company posted bleak fourth-quarter earnings. “The company looks very undervalued when you consider that it is capped at just over $200 million, and it has $50 million in net cash plus property and a plant in Adelaide worth $60-$70 million,” said Anton Tagliaferro, a veteran funds manager, who holds the stock. He runs a small-cap fund called Fundamental Investment Management. “This essentially means that the company’s U.S. women’s health and dermatology businesses, which have combined net sales of over $300 million, are being effectively valued at around $100 million which is very low.” Although there is no formal push to force the board’s hand, which would be possible if investors who hold at least 5% of the shares requisition an extraordinary general meeting, key shareholders are not ruling out drastic action, such as a board spill in the future. “There is significant dissatisfaction among the shareholder base,” said Brett Wells, whose family owns about 2% of the stock. He said a challenge was inevitable “without a substantive pivot by the board, and retirement of the chair.” Investors were frustrated at the $800 million in cumulative net operating losses over the past four years and the management’s handling of the failed Cosette takeover, Wells said. Mayne’s chief executive, Shawn O’Brien, stepped down in February and was replaced by its finance chief, Aaron Gray. “Mayne Pharma is not viable as an ongoing entity as it does not have sufficient scale,” Wells said. “The initial goal should be disposal of the branded drugs to an acquirer – it's timely as it's currently a hot area in the United States.” Shareholders want the board to sell Mayne's Adelaide manufacturing plant, which employs 200 people and was at the center of Chalmers' decision to block the takeover bid. Cosette, which wanted a way out of the deal, had threatened to close the plant if its bid was successful. That asset sale would clear the way for the sale of Mayne's U.S. women's health franchise and dermatology business, which account for the bulk of the company's earnings, said the shareholders. “We believe there would be many U.S. companies who would pay a very good price for Mayne's U.S. operations as we believe they would be a very valuable addition to an existing operation there,” Tagliaferro said. Pressure on the management has increased after Mayne Pharma posted a 6% fall in fiscal 2026 revenues and a 33% drop in underlying pre-tax earnings last week. However, the company’s shares have risen 20% since Friday when investor Jeremy Raper posted a note calling for it to be broken up. “85% of (Mayne’s) revenue is earned in the United States – $U.S.212 million ($301 million) of U.S. sales against $384 million of group revenue inside a sleepy, Australian-listed, Adelaide-domiciled corporate entity,” Raper wrote. “I should underline this key structural reason for the break-up: an ASX-listed small-cap whose core businesses are American women’s health and dermatology will never be appropriately valued in this market as currently structured.” Raper and other hedge fund investors said activist funds could force change at some point if the management did not act. Mayne Pharma declined to comment. Mayne’s shares were trading at $3.10 on Wednesday. Investors hope to get $5 to $7 per share in the event of a break-up and asset sales. Another shareholder, Hong Kong-based Maso Capital, which has a track record of securing change in Australian companies including Ramsay Health Care, also wants to see a strategic pivot. Other investors include London’s Trium Capital, San Francisco’s Funicular Funds and New York’s Rubric Capital Management. In Australia, Star Entertainment Group (ASX: SGR) chief executive Bruce Mathieson Jr. is a key shareholder. MST Marquee analyst Andrew Goodsall said Mayne Pharma's revenue decline last year partly reflected the upheaval caused by the failed Cosette bid, and softness in the dermatology business was being offset by positive momentum in the women's health business. Several investors believe Mayne's low valuation means it's ripe for a takeover, but are also wary that offshore bidders could be put off by the risk of the government intervening again to protect the Adelaide plant.

Read the article

8/5/2026

DGB Investments Pushes Furniture Firm Ethan Allen to Replace Board

Bloomberg (08/05/26) Sun, Mengqi

DGB Investments founder Douglas Bergeron has built a stake in Ethan Allen Interiors Inc. (NYSE: ETD) and is pushing to replace the furniture company’s entire board of directors. Bergeron believes Ethan Allen, despite its strong foundation, has failed to grow due to an outdated strategy and an over-tenured management and board, the investor said in a regulatory filing and letter to shareholders Wednesday, confirming a Bloomberg News report. As a result, he contends, the company has lost market share over the past two decades and trails competitors in annual revenue. Bergeron said he believes Ethan Allen has the potential to triple shareholder value over the next three years but the obstacle is the company’s leadership and governance. “I believe this iconic American business represents one of the most compelling opportunities in the public markets today,” Bergeron wrote. A former public company executive with a track record of turning around businesses, Bergeron has nominated himself and five others to replace the board. The others include former executives at eBay Inc. (NASDAQ: EBAY), Wayfair Inc. (NYSE: W) and Neiman Marcus Group who would bring expertise on retail technology, store operations, digital marketplaces and brand building, he said. A representative for Ethan Allen didn’t immediately respond to a request for comment. Ethan Allen last week reported a 5.7% year-over-year decline in net sales for the fiscal year ended June 30. The Danbury, Connecticut-based company offers free interior design service to clients and sells a range of home furnishings, including dressers, sofas and wall decor. The company's shares, which have fallen 18% over the past year, rose 1.9% to $24.34 at 10:14 a.m. in New York on Wednesday, giving the company a market value of about $619 million. DGB Investments, which is Bergeron's family office, and his family trusts hold 5% of the shares, the filing shows. Bergeron believes that Ethan Allen has a good brand, deep manufacturing capabilities in North America and a national retail footprint, but its strategy failed to focus on digital initiatives as online sales continue to grow in the furniture industry, he said in the letter. He added that the company's management team and board are unprepared to implement the changes. “I’ve seen it firsthand: companies fall behind when leadership is complacent, resistant to changing strategy and unwilling to make the difficult decisions necessary to drive growth,” he wrote. Farooq Kathwari has been serving as Ethan Allen’s chairman and chief executive officer since 1988 and hasn’t disclosed a succession plan. The board was reduced to five members after the sixth director, John Dooner Jr., died in January. Kathwari didn’t immediately respond to a request for comment. Bergeron, based in Park City, Utah, previously served as a co-managing partner at Hudson Executive Capital. In that role, he ran a successful proxy fight in 2020 at self-service payment technology firm Cantaloupe Inc. that led to a full board turnover, with him serving as the company’s chairman. Cantaloupe was sold this year for $848 million to retail technology firm 365 Retail Markets. Bergeron was previously CEO and chairman of payment processing company VeriFone, after it was spun off from Hewlett-Packard Co. (NYSE: HPQ) in 2001.

Read the article

8/5/2026

Investor Pressure Pushes Eagan-Based Solventum to Divest Billion-Dollar Business

Minnesota Star Tribune (08/05/26) Kennedy, Patrick

Solventum (NYSE: SOLV), which spun off from 3M in 2024, is divesting a division with $1.4 billion in annual sales. Under pressure, the Eagan-based company said Wednesday the divestiture of its Health Information Systems (HIS) unit will allow it to focus on its dental segment and its MedSurg unit, which sells medical products and surgical devices. Company officials said they have not decided whether to spin off or sell the unit, but they anticipate the process will take 12 to 18 months. The fund is one of Solventum’s largest shareholders, owning almost 5% of the company’s outstanding shares. Officials from Trian declined to comment on Wednesday’s announcement. Solventum Chief Executive Bryan Hanson told analysts on the company’s second quarter earnings call Wednesday that it has received interest in HIS from outside parties but expects more suitors to emerge after the announcement. While HIS is a billion-dollar unit, as a software provider to health care systems, it is different than Solventum's other businesses. A divestiture would focus Solventum more on medical technology. “We believe separation can unlock value by enabling both businesses to pursue distinct growth agendas, accelerate innovation and realize their full potential,” Hanson said in the company's news release. Solventum as a whole had revenue of $8.3 billion in 2025. The company's main businesses provide advanced wound care products, surgical supplies, stethoscopes, medical tapes and wraps and other medical technologies, dental and orthodontic products. Solventum sharpened that portfolio already last year by selling its purification business to Thermo Fisher Scientific (NYSE: TMO) for $4 billion. Maplewood-based 3M Co. (NYSE: MMM) spun off Solventum in April 2024. Hanson told analysts that the HIS business had been operating more or less independently since then, making a separation relatively easy. Analysts questioned the timing. Most divestitures are announced when plans are finalized. Hanson said public messaging around the topic was raising internal and external questions, and the company had made the decision to divest the unit. “It put us in a position where we had to communicate it and make sure we can control that messaging,” Hanson said on the earnings call. The company also reported its second quarter results Wednesday. It earned $92 million, or 53 cents a share, up from $90 million, or 51 cents a share in the same period a year ago. Adjusted earnings were $2.55 a share, handily beating analyst estimates of $1.91 a share. The HIS business grew 4.3% in the quarter, providing $354 million in revenue. It has been growing slower than the other larger segments. Total reported sales for the quarter, including the divestiture of the purification business, increased 2.2% to $2.2 billion. Solventum also raised its guidance for the year, saying organic sales would grow more and adjusted earning per share would be between $7.10 and $7.20. Previously, the company estimated yearly EPS would be $6.40 to $6.60.

Read the article

8/5/2026

JPMorgan Chase Hires Lissauer for Activism Defense

Reuters (08/05/26) Herbst-Bayliss, Svea

JPMorgan Chase (JPM.N) is hiring Bank of America (BAC.N) executive Amy Lissauer, a veteran adviser to companies facing pressure from investors, to bolster its global shareholder engagement practice, according to a memo seen by Reuters. JPMorgan said on Wednesday that Lissauer will join later this year as the global head of Shareholder Engagement and M&A Capital Markets (SEAMAC). She will be a global chair and be based in New York, the memo said. She was global head of Activism & Raid Defense at Bank of America. JPMorgan has over the last 18 months expanded its team that works with corporate clients under attack from prominent hedge funds that push for changes. Activism defense, once a nice-to-have add-on service, is now a lucrative business that major investment banks and many boutiques are scrambling to offer clients. Investors stepped up campaigns against global companies in the first half of 2026, with calls for businesses to sell themselves emerging as the most common demand, Barclays (NYSE: BCS) data showed. Bank of America hired Lissauer from Evercore (NYSE: EVR) in 2019. Since then, she has advised companies including Southwest Airlines (NYSE: LUV) in its defense against Elliott Investment Management and Norfolk Southern (NYSE: NSC) its fight against Ancora Alternatives. At Evercore she worked with Bill Anderson, one of the industry's most prominent defense bankers. The Financial Times first reported the move. At JPMorgan she will report to Filippo Gori and John Simmons, co-heads of Global Banking, the memo said, adding that "the SEAMAC senior leadership team will report to Amy." Lissauer is the latest in a string of bankers to leave Bank of America. The bank announced earlier on Wednesday that technology banker Ed Liu has resigned and plans to join a competitor.

Read the article